BioSpace News Archive

Halberd Corporation confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer’s Disease antibodies, Tau and Phosphorylated Tau.

Cortexyme, Inc. announced that it will present two poster presentations at the Alzheimer’s Association International Conference® 2021 (AAIC®) taking place July 26-30, 2021, in Denver, Colorado, as well as virtually.

Twist Bioscience Corporation today announced that it has started shipping its synthetic RNA reference controls for the SARS-CoV-2 Delta (B.1.617.2) and B.1.617.3 variants first identified in India and spreading rapidly worldwide.

ImmunoPrecise’s PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Monday, August 9, 2021, before market open.

Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug Application (IND) for ATRS-1902 for adrenal crisis rescue

RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), developer of patented technologies for the regeneration of skin and other organs and tissues, today provided an update on its clinical trial evaluating the safety and feasibility of the SkinGun™ and CellMist™ System to facilitate wound healing using skin cells obtained directly from the burn patient.

EOM Pharmaceuticals, Inc., a privately held, clinical-stage company, today announced the appointment of Frank L. Douglas , Ph.D., M.D., to Scientific Advisor.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, has issued a Letter to Stockholders updating its recent financing, the FDA regulatory process for RGN-259, and its 12-month operating strategy.

DURECT Corporation announced that it will report its second quarter 2021 financial results and host a conference call after the market close on Thursday, July 29, 2021.